基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

休市中 06-18 16:08:08

4.630

+0.070

+1.54%

最高4.810	最低4.500	成交量1,315万
今开4.550	昨收4.560	日振幅6.80%
总市值74.13亿	流通市值74.13亿	总股本16.01亿
成交额6,080万	换手率0.82%	流通股本16.01亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":4.63,"timestamp":1781770088006,"preClose":4.56,"halted":0,"volume":13146000,"delay":0,"changeRate":0.01535087719298252,"floatShares":1601000000,"shares":1601000000,"eps":-0.314752,"marketStatus":"休市中","change":0.07,"latestTime":"06-18 16:08:08","open":4.55,"high":4.81,"low":4.5,"amount":60799937,"amplitude":0.067982,"askPrice":4.63,"askSize":256500,"bidPrice":4.58,"bidSize":86000,"shortable":3,"etf":0,"ttmEps":-0.302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":7,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":4.56,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"volumeRatio":1.399537481921631,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616/tweets","defaultTab":"tweets","newsList":[{"id":"1127870307","title":"基石药业-B四日累计回购283.6万股，涉资约1,319.14万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127870307","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127870307?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:36","pubTimestamp":1781789790,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年6月18日披露公告显示，公司自2026年6月15日至6月18日连续四日回购股份，数量合计2,836,000股，约占公司已发行股本的0.1772%。当日回购股份500,000股，最高回购价格4.63港元，最低回购价格4.54港元，单日耗资2,314,345港元。四日回购总金额约13,191,400港元。公告显示，截至上述交易完成后，由于购回股份尚未注销，公司已发行股本及库藏股数量与回购前保持不变，仍为1,600,749,183股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B四日累计回购283.6万股，涉资约1,319.14万港元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644089543","title":"基石药业-B(02616)6月18日斥资231.43万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644089543","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644089543?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:32","pubTimestamp":1781789551,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，于2026年6月18日斥资231.43万港元回购50万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130273615","title":"基石药业-B：6月17日回购100万股股份，总额约462.12万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130273615","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130273615?lang=zh_cn&edition=full","pubTime":"2026-06-17 18:35","pubTimestamp":1781692555,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年6月17日发布翌日披露报表。公告显示，公司于当日于香港联交所场内回购普通股合计1,000,000股，约占公司已发行股本0.0625%。每股回购价在4.53港元至4.83港元之间，合计耗资约462.12万港元。根据公告，基石药业-B于2026年6月15日至6月17日期间先后多次回购股份，合计回购2,336,000股，将予以注销，约占公司于2025年6月25日购回授权通过当日已发行股本的0.1712%。本次回购完成后，公司已发行股本仍为1,600,749,183股，持有的库藏股数量为0股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B：6月17日回购100万股股份，总额约462.12万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644792215","title":"基石药业-B(02616)回购增持双管齐下，六月以来多位董事密集增持累计增持逾180万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644792215","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644792215?lang=zh_cn&edition=full","pubTime":"2026-06-17 10:59","pubTimestamp":1781665161,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据香港联交所最新披露，基石药业-B于迎来多位董事的集中增持。自6月初以来，执行董事杨建新博士、非执行董事李伟、胡正国Hitchner III Kenneth Walton四位董事已累计增持约180.65万股，按各笔均价估算涉资逾800万港元。其中，杨建新博士自2022年8月担任CEO以来，已以自有资金累计持有逾1338万股，持股比例达4.54%，彰显其长期绑定公司发展的决心。此外，基石药业于6月15日开始实施回购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107430308","title":"基石药业-B连续两日回购约133.6万股，涉资约625.58万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107430308","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107430308?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:41","pubTimestamp":1781620914,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年6月16日公布，近日通过香港联交所场内先后于2026年6月15日回购6,000股股份，回购价格为每股港币4.66元，占当日公司已发行股本约0.0004%；并于2026年6月16日再度回购1,330,000股股份，占已发行股本约0.0831%，每股回购价格介乎港币4.61元至4.74元，平均回购价为港币4.6826元，合计支付约港币622.78万元。两日内公司合计回购约1,336,000股股份，涉及总金额约港币625.58万元。回购股份尚未注销，截至2026年6月16日，公司已发行股本总数维持在1,600,749,183股，库藏股数为零。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B连续两日回购约133.6万股，涉资约625.58万港元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643376324","title":"基石药业-B(02616)6月16日斥资622.78万港元回购133万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643376324","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643376324?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:37","pubTimestamp":1781620668,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，于2026年6月16日斥资622.78万港元回购133万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121969312","title":"基石药业-B回购6,000股股份，总额约2.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121969312","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121969312?lang=zh_cn&edition=full","pubTime":"2026-06-15 22:06","pubTimestamp":1781532392,"startTime":"0","endTime":"0","summary":"2026年6月15日，基石药业-B（02616）于香港联交所发布翌日披露报表，公告公司于当日于场内回购6,000股普通股，占已发行股本约0.000004%。每股回购价格为4.66港元，合计动用资金27,960港元（折合约2.80万港元）。\n公告显示，本次回购后，公司已发行股本于2026年6月15日仍为1,600,749,183股，库藏股维持0股。公司此前已于2025年6月25日通过购回授权，授权可回购股份总数为136,439,723股，本次回购占该授权通过日已发行股本的约0.00004%。\n公司确认本次回购符合香港联交所证券上市规则及相关法律法规要求。公告由公司董事李伟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B回购6,000股股份，总额约2.80万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643209020","title":"基石药业-B(02616)6月15日斥资2.8万港元回购6000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643209020","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643209020?lang=zh_cn&edition=full","pubTime":"2026-06-15 22:02","pubTimestamp":1781532164,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，于2026年6月15日斥资2.8万港元回购6000股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642250606","title":"港股异动 | 基石药业-B(02616)尾盘涨近5% CS5007全球多中心I期临床试验启动 高管增持彰显发展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2642250606","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642250606?lang=zh_cn&edition=full","pubTime":"2026-06-12 15:05","pubTimestamp":1781247958,"startTime":"0","endTime":"0","summary":"消息面上，基石药业宣布，公司管线2.0核心候选药物CS5007的全球多中心I期临床试验，已正式获得澳大利亚人类研究伦理委员会的许可。这不仅标志着CS5007的全球临床开发全面启动，更意味着公司管线2.0战略正加速兑现，后续重磅力量已进入临床快车道，有望为中长期增长持续注入信心。值得注意的是，基石药业近期获多位董事增持力挺。管理层表示当前股价严重低估，侧面看好CS2009授权谈判进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","BK4588","VXUS","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642258162","title":"近一周增持110万股！董事大举增持释放积极信号 基石药业-B(02616)打开长期增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2642258162","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642258162?lang=zh_cn&edition=full","pubTime":"2026-06-12 08:30","pubTimestamp":1781224200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，头部创新药企基石药业-B近期获多位董事增持力挺。多名董事近一周合计增持110万股，涉资约495万港元，这既是对其资产价值的理性判断，更是对公司未来发展价值的强力背书。杨建新博士此前表示，股份增持计划彰显了董事及高级管理层对公司产品管线全球竞争力的坚定信心。总的来看，在高管密集增持、临床试验数据持续亮眼和创新管线稳步推进的多重利好共振之下，基石药业有望进一步释放成长预期，为投资者创造长期价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"近一周增持110万股！董事大举增持释放积极信号 基石药业-B(02616)打开长期增长空间","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237365","title":"基石药业-B(02616)：CS5007(EGFR/HER3双特异性ADC)全球多中心I期临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237365","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642237365?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:10","pubTimestamp":1781215804,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，本公司管线2.0核心候选药物CS5007的全球多中心I期临床试验，已正式获得澳大利亚人类研究伦理委员会的许可。这不仅标志着CS5007的全球临床开发全面启动，更意味着本公司管线2.0战略正加速兑现，后续重磅力量已进入临床快车道，有望为中长期增长持续注入信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4231","ADC","02616","BK4080","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642742805","title":"执行董事兼首席执行官杨建新增持基石药业-B(02616)14.5万股 每股作价约4.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642742805","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642742805?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:52","pubTimestamp":1781088749,"startTime":"0","endTime":"0","summary":"6月10日，执行董事兼首席执行官杨建新增持基石药业-B(02616)14.5万股，每股作价4.2593港元，总金额约为61.76万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260610/20260610185255_12629.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260610/20260610185255_12629.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","EWH","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148362","title":"康方新药取得历史性突破，为何蒸发百亿市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148362","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641148362?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:42","pubTimestamp":1780659720,"startTime":"0","endTime":"0","summary":"6月1日，康方生物开盘后一度涨超12%，然而高开低走，此后三日连续下跌，截至6月5日收盘，康方生物总市值862亿港元，数日内市值跌去超百亿。在康方生物的叙述中，这份登陆ASCO全体会议的临床数据堪称历史性突破。无可辩驳的是，康方生物的HARMONi-6已达到全部预期终点，取得显著阳性。股价为何下跌数据公布后3日，康方生物的市值跌去超百亿港元，截至发稿，总市值已不足千亿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0561508036.HKD","LU0540923850.HKD","HR","LU0348827113.USD","LU0348767384.USD","PFS","LU0417516902.SGD","LU2476274720.SGD","IE00BPRC5H50.USD","LU2778985437.USD","IE00B543WZ88.USD","BK1161","09926","LU0348735423.USD","LU0348784397.USD","BK1574","LU0417516571.SGD","BK4225","LU0348825331.USD","LU2476274308.USD","LU2399975544.HKD","BK4195","06978","BK4211","LU0634319403.HKD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1720050803.USD","LU2488822045.USD","BK4203","LU0348766576.USD","LU1961090484.USD","LU0417516738.SGD","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179641013","title":"基石药业-B5月股份变动月报表：股本略有增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1179641013","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179641013?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:41","pubTimestamp":1780562518,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年6月4日发布截至2026年5月31日的股份变动月报表。公告显示，公司于报告期内总股本较上月小幅增加，注册股本维持不变。以下为本次披露的要点：。本期公司注册股本为2,000,000,000股，每股面值为0.0001美元，总额200,000美元，与上月一致。截至5月末，已发行普通股股份数量由上月底的1,600,249,187股增至1,600,749,183股，增加499,996股；报告期内并无产生或注销库藏股。报告期内未涉及购回或赎回股份事项。本公告由公司董事李伟签署，公告日期为2026年6月4日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640138210","title":"杰富瑞(Jefferies)：高管增持彰显发展信心 CS2009临床数据亮眼确立BD预期 维持基石药业-B(02616)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2640138210","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640138210?lang=zh_cn&edition=full","pubTime":"2026-06-04 08:38","pubTimestamp":1780533520,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，杰富瑞发布研报称，基石药业-B管理层增持计划印证公司对管线授权洽谈的信心。该行看好CS2009商业化与授权潜力，维持基石药业“买入”评级，目标价20港元，较现价有298%上涨空间。杰富瑞主要观点如下：管理层增持股份，看好CS2009商务授权前景公司管理层及董事会拟增持公司股票，充分印证管理层对管线BD进展的高度信心。临床数据证实CS2009可改善肿瘤微环境免疫抑制，让既往免疫治疗无效患者获益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"杰富瑞(Jefferies)：高管增持彰显发展信心 CS2009临床数据亮眼确立BD预期 维持基石药业-B(02616)“买入”评级","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165373917","title":"基石药业-B宣布CEO、董事及高级管理层启动联合购股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1165373917","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165373917?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:40","pubTimestamp":1780483217,"startTime":"0","endTime":"0","summary":"基石药业-B（2616.HK）于6月3日宣布，其首席执行官、董事会成员及高级管理层已共同启动一项股份购买计划。根据该计划，相关人士拟自2026年6月起，在公开市场联合购入总计200万至500万股公司股份。\n此项联合购股行动彰显了公司核心管理层对基石药业-B未来长期发展前景的坚定信心，并体现了其与股东利益深度绑定的决心。管理层通过真金白银投入市场，直接参与股份增持，旨在向投资者传递积极的信号。\n计划的具体实施细节将遵循相关市场规则与披露要求。市场分析人士认为，此类内部人士的集体购股行为，通常被视作对公司内在价值和增长潜力的认可，可能对市场情绪产生正面影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640969903","title":"基石药业-B(02616)董事及高管拟增持200万股至500万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640969903","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640969903?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:03","pubTimestamp":1780481018,"startTime":"0","endTime":"0","summary":"增持将于2026年6月起至刊发集团截至2026年6月30日止六个月的中期业绩禁售期开始前进行，增持股份总数为200万股至500万股公司股份。公司董事会认为，董事及高级管理层进行的股份增持，充分体现了彼等对公司作出的长期承诺以及对公司未来业务前景的坚定信心。董事会相信，该等增持行为符合公司及其股东的整体最佳利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B(02616)董事及高管拟增持200万股至500万股公司股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199739469","title":"异动解读 | 竞争药物数据超预期引发担忧，基石药业-B盘中大跌8.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199739469","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199739469?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:23","pubTimestamp":1780385002,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中股价大幅下挫，跌幅一度达到8.64%，引起市场关注。消息面上，高盛在最新发布的报告中指出，公司股价此前已出现显著波动。这一强劲数据引发了市场对于基石药业核心在研产品CS2009未来市场竞争格局及监管审批路径的担忧，尽管高盛同时给予公司“买入”评级并认为CS2009的监管路径预期将保持清晰。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640990449","title":"高盛：发布ASCO后最新报告 给予基石药业-B(02616)“买入”评级 目标价为 9.44 港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640990449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640990449?lang=zh_cn&edition=full","pubTime":"2026-06-02 14:54","pubTimestamp":1780383286,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，给予基石药业-B“买入”评级，基于风险调整后DCF的12个月目标价为 9.44港元。该行重申对 CS2009 所展现的整体药物特性的积极看法，并强调执行是关键，因为基石药业的目标是在 2026 年底前启动首批 III 期 MRCT 并达成一项业务发展交易。该行重申 CS2009 总体耐受性良好，并预计在后期试验中具有相似的安全性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176228064","title":"基石药业-B拟回购不超过已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176228064","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176228064?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:11","pubTimestamp":1780319492,"startTime":"0","endTime":"0","summary":"基石药业-B于6月1日发布公告，拟在股东周年大会上申请授权，回购不超过公司于股东大会通过当天已发行股本总数10%的股份。公司当前已发行股份总数约为1,600,749,183股，回购规模上限约为160,074,918股。股权登记截止日为6月23日，股东及股东代理人可于当天大会上就回购议案进行表决。董事会强调，此次回购将不会导致该公司公众持股比例低于香港联交所的最低持股要求。董事会认为，本次回购计划符合公司和股东的整体利益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B拟回购不超过已发行股本10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":0.0381},{"period":"1month","weight":-0.3884},{"period":"3month","weight":-0.3241},{"period":"6month","weight":-0.2309},{"period":"1year","weight":0.0818},{"period":"ytd","weight":-0.1214}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0535},{"period":"6month","weight":-0.0687},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.031371},{"month":5,"riseRate":0.428571,"avgChangeRate":0.066954},{"month":6,"riseRate":0.625,"avgChangeRate":0.029521},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05639},{"month":8,"riseRate":0.428571,"avgChangeRate":0.079119},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.071005},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}